Cargando…
Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients
INTRODUCTION: Disease-modifying treatments for Alzheimer's disease (AD) are likely to be offered only to patients with molecular evidence for Alzheimer pathology and expanded to patients with prodromal AD. We calculated the potential future costs of expanding the number of positron emission tom...
Autores principales: | Wittenberg, Raphael, Knapp, Martin, Karagiannidou, Maria, Dickson, John, Schott, Jonathan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709060/ https://www.ncbi.nlm.nih.gov/pubmed/31463360 http://dx.doi.org/10.1016/j.trci.2019.06.001 |
Ejemplares similares
-
Neural and behavioral substrates of disorientation in mild cognitive impairment and Alzheimer's disease
por: Sousa, Amber, et al.
Publicado: (2015) -
Cognitive and structural cerebral changes in amnestic mild cognitive impairment due to Alzheimer's disease after multicomponent training
por: Teixeira, Camila Vieira Ligo, et al.
Publicado: (2018) -
Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment
por: Wang, Guoqiao, et al.
Publicado: (2015) -
The effect of statins on rate of cognitive decline in mild cognitive impairment
por: Smith, Kyle B., et al.
Publicado: (2017) -
Predicting mild cognitive impairment from spontaneous spoken utterances
por: Asgari, Meysam, et al.
Publicado: (2017)